-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Inotiv, Inc. to Participate in Upcoming Investor Conferences
Inotiv, Inc. to Participate in Upcoming Investor Conferences
WEST LAFAYETTE, Ind., May 16, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the "Company", "We", "Our" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences:
UBS Global Healthcare Conference
New York City
May 23-25, 2022
Group presentation: Tuesday, May 24, 2022 at 7:45 a.m. ET
Craig-Hallum Institutional Investor Conference
Virtual
June 1, 2022
One-on-one and small group meetings only
Jefferies Healthcare Conference
New York City
June 8-10, 2022
Group presentation: Friday, June 10, 2022 at 12:15 p.m. ET
A webcast of the UBS and Jefferies group presentations will be accessible on the Company's website at:
Inotiv management will be participating in one-on-one meetings during all events.
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Company Contact | Investor Relations |
Inotiv, Inc. | The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA |
(765) 497-8381 | (212) 836-9614 |
btaylor@inotivco.com | kahl@equityny.com |
Devin Sullivan | |
(212) 836-9608 | |
dsullivan@equityny.com |
WEST LAFAYETTE, Ind., May 16, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the "Company", "We", "Our" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, are scheduled to participate in the following investor conferences:
印第安納州西拉斐特,2022年5月16日(環球通訊社)伊諾諾夫公司(納斯達克:NOTIV)(“公司”、“我們”、“我們的”或“伊諾維奇”)專門從事非臨牀和分析性藥物發現和開發服務以及研究模型和相關產品和服務的領先合同研究機構今天宣佈,總裁兼首席執行官小羅伯特·利蘇爾和首席財務官貝絲·泰勒計劃參加以下投資者會議:
UBS Global Healthcare Conference
New York City
May 23-25, 2022
Group presentation: Tuesday, May 24, 2022 at 7:45 a.m. ET
瑞銀全球醫療保健大會
紐約市
2022年5月23日至25日
小組報告時間:2022年5月24日,星期二,上午7:45外星人
Craig-Hallum Institutional Investor Conference
Virtual
June 1, 2022
One-on-one and small group meetings only
克雷格-哈勒姆機構投資者大會
虛擬
2022年6月1日
僅限一對一和小組會議
Jefferies Healthcare Conference
New York City
June 8-10, 2022
Group presentation: Friday, June 10, 2022 at 12:15 p.m. ET
傑富瑞醫療會議
紐約市
2022年6月8日至10日
小組報告:2022年6月10日,星期五,下午12:15外星人
A webcast of the UBS and Jefferies group presentations will be accessible on the Company's website at:
瑞銀集團和傑富瑞集團演示文稿的網絡直播將在公司網站上收看,網址為:
Inotiv management will be participating in one-on-one meetings during all events.
在所有活動期間,INotiv管理層將參加一對一的會議。
About Inotiv
關於INotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:
伊諾諾夫公司是一家領先的合同研究機構,致力於提供非臨牀和分析性藥物發現和開發服務以及研究模型和相關產品和服務。該公司的產品和服務側重於通過發現和臨牀前開發階段帶來新藥和醫療設備,同時提高效率、改善數據並降低將新藥推向市場的成本。INotiv致力於支持發現和開發目標,並幫助研究人員實現其關鍵研發項目的全部潛力,同時共同努力建設一個更健康、更安全的世界。有關Inov的更多信息可在此處找到:
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
本新聞稿可能包含前瞻性陳述,這些陳述會受到風險和不確定性的影響,這些風險和不確定性包括但不限於與以下因素有關的風險和不確定性:市場和對我們產品和服務的需求的變化;產品和服務的開發、營銷和銷售;技術、行業和監管標準的變化;收購的時機和成功完成收購的時間;整合及其對業務和財務的影響;新冠肺炎大流行對經濟的影響;對我們的服務和產品以及我們的運營的需求;包括政府當局為應對可能導致或加劇其他風險和/或不確定性的大流行而採取的措施;擴張及相關努力;以及其他各種市場和經營風險,包括公司提交給美國證券交易委員會的文件中詳細説明的風險。
Company Contact | Investor Relations |
Inotiv, Inc. | The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA |
(765) 497-8381 | (212) 836-9614 |
btaylor@inotivco.com | kahl@equityny.com |
Devin Sullivan | |
(212) 836-9608 | |
dsullivan@equityny.com |
公司聯繫人 | 投資者關係 |
伊諾諾夫公司 | 股權集團公司。 |
首席財務官貝絲·A·泰勒 | Kalle Ahl,CFA |
(765) 497-8381 | (212) 836-9614 |
郵箱:btaylor@intivco.com | 郵箱:kahl@equityny.com |
德文·沙利文 | |
(212) 836-9608 | |
郵箱:dsullivan@equityny.com |
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧